Drug Trial Radar · NCT03977207
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
336
Planned (sponsor's estimate)
Start
Jul 20, 2020
Primary completion
Nov 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- University of California, IrvineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Jun 6, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication in chronic kidney disease patients, and prior evidence shows that higher TSH levels, even within the normal laboratory range, are strongly associated with impaired quality of life and cardiovascular disease in this population. Levothyroxine is one of the most frequently prescribed medications in chronic kidney disease, yet its efficacy and safety in these patients have not been well-studied. Hence, this study will investigate 1) whether levothyroxine improves patient-centered (e.g., health-related quality of life, physical performance, strength) and 2) cardiovascular (e.g., coronary artery calcification, endothelial function, systolic function) outcomes in dialysis patients, and 3) if thyroid hormone replacement exerts classic metabolic effects (i.e., changes in body fat and resting energy expenditure) in this population.
Conditions
- Thyroid; Functional Disturbance
- Hypothyroidism
- Hemodialysis
Interventions
Levothyroxine SodiumDrug
Thyroid hormone supplement
PlacebosDrug
Placebo oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 0 (pre-trial/baseline)
- Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 12
- Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 24
- Coronary Artery Calcification (CAC) - Volume ScoreTime frame: Week 0 (pre-trial/baseline)
- Coronary Artery Calcification (CAC) - Volume ScoreTime frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California Irvine
Orange, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.